ArticleBMJ open2019
Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study.
Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies.PloS one · 2024Pooled it
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2026Review
- Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial.Scientific reports · 2025Article
- Patterns and predictors of multiple sclerosis phenotype transition.Brain communications · 2024Article
- Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021.Neurology and therapy · 2023Article
- Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.International journal of molecular sciences · 2023Review
- Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Review
- Understanding quality of life across different clinical subtypes of multiple sclerosis: a thematic analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Key demographics and psychological skills associated with adjustment to progressive Multiple Sclerosis early in the diagnosis.Frontiers in rehabilitation sciences · 2022Article
- Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey.Health science reports · 2022Article
- How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?Journal of central nervous system disease · 2022Article
- Determinants of disability development in patients with multiple sclerosis.Arquivos de neuro-psiquiatria · 2021Article
- Development of a Web-Based Mindfulness Program for People With Multiple Sclerosis: Qualitative Co-Design Study.Journal of medical Internet research · 2021Article
- Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy.PloS one · 2020Article
- Construction of a User-Led Resource for People Transitioning to Secondary Progressive Multiple Sclerosis: Results of an International Nominal Group Study.Frontiers in neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTransitioning to secondary progressive multiple sclerosis (SPMS) is demanding for both patients and healthcare professionals. The particular challenges and the ways patients cope are poorly understood. The present study examines what challenges people face when diagnosed with SPMS by exploring experiences of people who have transitioned recently (up to 5 years).
designSemistructured qualitative interviews at two time points a year apart. Interviews were analysed using inductive thematic analysis.
settingUK.
participantsWe interviewed 21 people at baseline and 17 participated in the follow-up interviews.
resultsThe majority of participants reported expecting to transition to SPMS, and the diagnosis did not make much difference to them. Participants described increasing emotional and physical challenges after transitioning to SPMS and between the first and second interviews. Planning, using distractions and maintaining social roles helped participants cope with the increased challenges. The same coping strategies were used between the two interviews. Participants felt there was not much left to do regarding the management of their symptoms. A key theme was the sense of abandonment from healthcare services after transitioning to SPMS.
conclusionsAfter transitioning to SPMS, people are faced with multiple challenges. Participants described a lack of directions for symptoms management and lack of support from the healthcare system. An integrated multidisciplinary healthcare approach is crucial at the progressive stage of the disease to alleviate feelings of helplessness and promote symptom management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.